A. Ruiz
University of Alcalá
33 Papers
236 Citations
A. Ruiz is an academic researcher from University of Alcalá. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 10, co-authored 32 publications.
Chat about Author
Papers
Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study
M. Martin,A. Lluch,M. A. Seguí,Antonio Antón,A. Ruiz,Manuel Ramos,Álvaro Rodríguez-Lescure,Encarna Adrover +7 more
TL;DR: Within the limitations of a non-randomized comparison, the use of G-CSF beginning with the first cycle of TAC substantially reduces the incidence of FN and other gr 3/4 toxicities and enables maintenance of chemotherapy dose intensity for women with early stage breast cancer.
33
Preoperatively irradiated rectal carcinoma: analysis of the histopathologic response and predictive value of proliferating cell nuclear antigen immunostaining.
Díez M,P. Ramos,María José Medrano,Mugüerza Jm,R. Villeta,O. Lozano,J.A. Escribano,F. Noguerales,A. Ruiz,J. Granell +9 more
TL;DR: High proliferative activity of rectal cancer, as determined by PCNA immunostaining, is predictive of the response to preoperative chemoradiotherapy.
28
•Journal Article
Histopathologic prognostic score in colorectal adenocarcinomas.
Díez M,Marina Pollán,J.M. Enriquez,P Domínguez,A Santana,Tobaruela E,Mugüerza Jm,Arrieta F,Antonia Rodriguez,A. Ruiz +9 more
TL;DR: A prognostic score based in the evaluation of four histopathologic parameters concerning the tumor phenotype enables the identification of groups of patients at risk of relapse after curative resection for colorectal adenocarcinoma.
21
Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GEICAM Study 9805
M. Martin,A. Lluch,M. A. Seguí,Antonio Antón,C. Fernandez-Chacón,A. Ruiz,Manuel Ramos,Encarna Adrover,Álvaro Rodríguez-Lescure,A. Casado +9 more
TL;DR: Node-positive BC pts treated with TAC have a longer disease-free and overall survival but a higher rate of febrile neutropenia (FN) compared with pts treating with FAC.
21
•Journal Article
P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
Díez M,María José Medrano,A. Gutiérrez,López A,Mugüerza Jm,Pilar Hernández,O. Lozano,F. Noguerales,A. Ruiz,J. Granell +9 more
TL;DR: The results suggest that postoperative adjuvant chemotherapy acted differently in p53-positive than in p 53-negative gastric tumors, and absence of p53 overexpression is associated to longer survival when adjuant therapy is administered.
20